Search

Displaying results 2891 - 2900 of 10000 in total
  1. Drug

    Dexmethylphenidate

    go.drugbank.com/drugs/DB06701
    ApprovedInvestigational

    Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181].

  2. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  3. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. … These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.

    Synonyms: N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea
  4. Drug

    Maltose

    go.drugbank.com/drugs/DB03323
    Investigational

    It is used as a sweetening agent and fermentable intermediate in brewing (Grant & Hackh's Chemical Dictionary, 5th ed).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.

  6. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [A39838] This type of molecules is currently in development for veterinary patients.[A39816] This class of drugs was defined in 2013 by the World Health Organization.

  7. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

  8. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated … [L63809,L63931] At the time the labeling was issued in May 2026, both the initial U.S. approval date and the controlled substance schedule remained pending review by the Drug Enforcement Administration

  9. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228423, A228758] As a result of its anticholinergic effects, scopolamine is being investigated for diverse therapeutic applications; currently, it is approved for the prevention of nausea and vomiting … [A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse

  10. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane.